SSGJ-611 vs stapokibart

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline

SSGJ-611

Developed by Sunshine Guojian Pharmaceutical and partners

Phase 3 in Atopic Dermatitismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2027 · NCT07767253 (registry estimate)

No aligned efficacy figure on record for this race.

stapokibart

Marketed by Keymed Biosciences and partners

Phase 3 in Atopic Dermatitismonoclonal antibody
Reliable signal

NCT05265923 · Phase 3 · completed

In this randomized, double-blind, placebo-controlled Phase 3 trial in 500 adults with moderate-to-severe atopic dermatitis, significantly more patients receiving stapokibart achieved at least a 75% reduction in eczema severity at 16 weeks than those on placebo (66.9% vs 25.8%).

Next expected readout: February 2027 · NCT07106372 (registry estimate)

Reported efficacy

Proportion of subjects achieving EASI-75 at week 18 (Up to week 18); Proportion of subjects with IGA score of 0 or 1 and a reduction of IGA score by ≥2 points from baseline (up to week 18): EASI-75 at week 18: 73.9% (88/119) stapokibart vs 43% (26/60) placebo; difference 30.5 percentage points (95% CI 15.3-44.3; P<0.001) (met)

Result source: NCT06277765

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSSGJ-611stapokibart
EASI-75—Not posted · NCT06173284—Not posted · NCT05265923
IGA 0/1 with 2-point improvement—Not posted · NCT06173284—Not posted · NCT05265923
EASI-90—Not posted · NCT06173284—Not posted · NCT05265923
EASI, % change—Not posted · NCT06173284—Not posted · NCT05265923

EASI-75

SSGJ-611
—Not posted · NCT06173284
stapokibart
—Not posted · NCT05265923

IGA 0/1 with 2-point improvement

SSGJ-611
—Not posted · NCT06173284
stapokibart
—Not posted · NCT05265923

EASI-90

SSGJ-611
—Not posted · NCT06173284
stapokibart
—Not posted · NCT05265923

EASI, % change

SSGJ-611
—Not posted · NCT06173284
stapokibart
—Not posted · NCT05265923
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SSGJ-611: no structured comparison results are available for Atopic Dermatitis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

stapokibart
EASI-75 response at week 16: 66.9% stapokibart vs 25.8% placebo (significantly higher) NCT05265923 · Phase 3 · design grade: strong · publication or press release
EASI-75 at week 18: 73.9% (88/119) stapokibart vs 43% (26/60) placebo; difference 30.5 percentage points (95% CI 15.3-44.3; P<0.001) NCT06277765 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SSGJ-611's landscape · stapokibart's landscape